Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Social Anxiety Disorder
NCT03078270Phase 4Terminated
- Start
- Feb 2017
- Primary completion
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of botulinum toxin type A in Social Anxiety Disorder (SAD). Started Feb 2017; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT03078270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03078270.